Biogen plans 4 phase study: Evaluation Benifit of SPINRAZA® (NUSINERSEN) in patients thats treated with ZOLGENSMA

CAMBRIDGE, Mass., July 21, 2020 Biogen Inc. (Nasdaq: BIIB) today announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma® (onasemnogene abeparvovec).

Vetenskapliga artiklar om spinal muskelatrofi

Publicerat av


Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg